Department of Laboratory Medicine, Konyang University Hospital, College of Medical Science Konyang University, Daejon, Republic of Korea.
Clin Chim Acta. 2011 Sep 18;412(19-20):1831-4. doi: 10.1016/j.cca.2011.06.014. Epub 2011 Jun 24.
Glimepiride is a commonly used sulfonylurea hypoglycemic agent. There is considerable interindividual variation in the response to sulfonylurea for patients with type 2 diabetes. The purpose of this study was to investigate whether genetic variations influence the efficacy of glimepiride in healthy Korean subjects.
A single 2-mg oral dose of glimepiride was administered to 46 healthy volunteers. Serial blood sampling for 12h after oral dosing was performed for determination of plasma glimepiride, glucose and insulin levels. We tested the association of seven single nucleotide polymorphisms (SNPs) in four candidate genes with the efficacy of glimepiride.
Pharmacodynamic profiles for plasma glucose and insulin showed no statistically significant differences among genotype groups, and parameters were not different from one another. There were no association of the KCNJ11, NOS1AP, TCF7L2 and ABCC8 gene polymorphisms and the efficacy of glimepiride.
Knowledge of these polymorphisms provides no clinical useful information for the pharmacogenetic therapeutic approach for Korean patients with type 2 diabetes.
格列美脲是一种常用的磺酰脲类降糖药。2 型糖尿病患者对磺酰脲类药物的反应存在相当大的个体差异。本研究旨在探讨基因变异是否影响健康韩国受试者格列美脲的疗效。
46 名健康志愿者单次口服 2mg 格列美脲。口服后 12 小时内进行连续采血，测定血浆格列美脲、血糖和胰岛素水平。我们检测了四个候选基因中的七个单核苷酸多态性（SNP）与格列美脲疗效的关系。
血浆葡萄糖和胰岛素的药效学特征在基因型组之间没有统计学上的显著差异，各参数之间也没有差异。KCNJ11、NOS1AP、TCF7L2 和 ABCC8 基因多态性与格列美脲的疗效无关。
这些多态性的知识不能为韩国 2 型糖尿病患者的药物遗传学治疗方法提供临床有用的信息。
